Biotechnology company Moderna (NASDAQ:MRNA) is set to report its quarterly results this Friday. Last quarter, Moderna exceeded revenue expectations by 32.2%, reporting $1.02 billion in revenues, down 45.1% year on year. This quarter, analysts expect revenues to decline 31.7% to $660.2 million. Moderna has historically beat revenue estimates, with analysts reconfirming their estimates leading up to earnings. Peers in the therapeutics segment, such as Biogen and Amgen, have reported mixed results. As the company heads into earnings, the outlook for 2025 remains uncertain amidst potential trade policy changes and corporate tax discussions.

Read more at Barchart: What To Expect From Moderna’s (MRNA) Q4 Earnings